<DOC>
	<DOCNO>NCT02426879</DOCNO>
	<brief_summary>There world-wide consensus oncological benefit versus increase morbidity associate three field lymphadenectomy patient esophageal cancer cervical lymph node metastasis . In Asian country , esophagectomy commonly combine three field lymphadenectomy , include resection cervical , thoracic abdominal lymph node . However , Western country patient cervical lymph node metastasis generally preclude curative treatment .</brief_summary>
	<brief_title>Esophagectomy Patients With Esophageal Cancer Cervical Lymph Node Metastases</brief_title>
	<detailed_description>Objective : To assess safety feasibility curative esophagectomy combine three field lymphadenectomy chemo-radiation Western patient resectable thoracic esophageal carcinoma cervical lymph node metastasis . Secondary objective determine effect survival recurrence . Study design : Mono centre prospective phase II single-arm feasibility study . Study population : Western patient diagnose resectable ( cT1-4a , N1-3 ) intra thoracic esophageal carcinoma histological cytological proven cervical lymph node metastasis level III and/ IV . Intervention : Transthoracic esophageal resection combine three field lymphadenectomy neoadjuvant chemo-radiation . Main study parameters/ endpoint : Primary outcome percentage overall surgical complication grade 3b high state Modified Clavien-Dindo classification . Secondary outcome mortality , operation related event postoperative recovery , include quality life , disease free survival , overall survival applicable location recurrent disease .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histologically proven squamous cell carcinoma adenocarcinoma esophagus . Surgical resectable carcinoma ( T14a , N13 ) ( table 1 ) Histologically/ cytologically proven resectable cervical lymph node metastasis level III and/ IV Age ≥ 18 ≤ 75years European Clinical Oncology Group ( ECOG ) performance status 0,1 2 Written inform consent Distant metastases Esophageal carcinoma &lt; 3 cm beneath UES Carcinoma gastroesophageal junction ( GEJ ) major tumor gastric cardia ( Siewert III ) Former radiotherapy chemotherapy esophageal carcinoma Former radiotherapy preclude radiotherapy accord CROSS protocol Inadequate pulmonary function disable transthoracic resection &gt; 10 % loss weight last six month Previous neck dissection New York heart association class III/IV history active angina . Patients history significant ventricular arrhythmia require medication congestive heart failure . History 2nd 3rd degree heart block</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>three-field lymphadenectomy</keyword>
	<keyword>cervical metastasis</keyword>
	<keyword>esophagectomy</keyword>
</DOC>